AUTHORS
Jessica Encinas Mayoral, PhD, Jian Cui, MD, PhD Candidate2, Elena Maroto Martin, PhD3, Alice Mattinson4, Edward King5, Marina He, BA6, Amanda Kofides, MSc7, Steven Treon, MD, PhD8, Zachary R Hunter, PhD9, Holly Lee, MD, PhD10, Paola Neri, MD, PhD11, Nizar Bahlis, MD12, Yulia Lampi13, Simon Bornschein, PhD14, Mehmet Kemal Samur, PhD15, Mariateresa Fulciniti, PhD16, Nikhil Munshi, MD17
AFFILIATIONS
1 Dana Farber Cancer Institute, Boston, Massachusetts, United States
2 Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianyin, China
3 Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre, Madrid, Spain
4 Coding Bio, Oxford, United Kingdom
5 Coding Bio, Oxford, United Kingdom
6 Dana Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana Farber Cancer Institute, Boston, Massachusetts, United States
10 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
11 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
12 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
13 Coding Bio, Oxford, United Kingdom
14 Coding Bio, Oxford, United Kingdom
15 Dana Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Although BCMA-directed immunotherapies have produced impressive clinical responses in multiple myeloma (MM), most patients ultimately relapse, often due to antigen loss, BCMA sequence variants, or other resistance mechanisms that limit durable benefit. In this setting, dual-antigen targeting through trispecific T-cell engagers (TriTEs) may help reduce antigen escape and broaden activity across heterogeneous disease. We selected FcRL5 as an attractive therapeutic target because it is broadly expressed in multiple myeloma (MM) and other B-cell malignancies, including Waldenström macroglobulinemia (WM), with minimal expression outside the B-cell lineage. Consistent with this, flow cytometry, RNA sequencing, and proteomic analyses demonstrated widespread FcRL5 expression across MM cell lines and primary patient samples.
Using an AI-guided high-throughput discovery platform, TriTE candidates were prioritized based on functional activity, including T-cell activation and tumor cell killing, rather than binding affinity alone. This approach identified CB-101 as the lead OR-gated BCMA/FcRL5 TriTE, selectively activating T cells only in the presence of BCMA- or FcRL5-expressing tumor cells.
In vitro, CB-101 induced comparable or superior tumor cell killing and T-cell activation than the FcRL5-targeting T-cell engager cevostamab or the BCMA-directed bispecific antibody teclistamab across MM cell lines, including bortezomib-resistant cell line models. CB-101 activity was further confirmed in primary MM samples in both allogeneic and autologous settings.
Importantly, CB-101 retained potent activity in BCMA-resistance models. In BCMA-knockout cells, CB-101 mediated greater cytotoxicity than teclistamab, and FcRL5 overexpression further enhanced tumor killing, outperforming both teclistamab and cevostamab. Notably, CB-101 remained active against clinically relevant BCMA escape variants (S30del and P34del) that are poorly recognized by teclistamab, supporting its potential to overcome established BCMA-mediated resistance mechanisms.
In two humanized disseminated MM mouse models, CB-101 demonstrated antitumor activity comparable to the BCMA/GPRC5D TriTE ramantamig and superior efficacy to teclistamab, achieving durable tumor control even at a 10-fold lower dose. Notably, all CB-101-treated mice remained alive beyond day 170, compared with a median survival of 82 days in the teclistamab-treated group.
Beyond MM, CB-101 demonstrated potent activity against WM cells, supporting the broader therapeutic potential of dual BCMA/FcRL5 targeting B-cell malignancies.
In conclusion, CB-101 is an AI-designed, OR-gated BCMA/FcRL5 TriTE that demonstrates superior preclinical activity compared with BCMA-directed therapy alone while retaining efficacy in models of antigen escape and clinically relevant BCMA resistance. These findings support the clinical development of CB-101 as a next-generation T-cell engager for MM and WM.
DISCLOSURES
Jessica Encinas Mayoral, PhD: Coding Bio - Consultancy (Includes expert testimony)